Literature DB >> 25186410

Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques.

Joshua Grimes1, Anna Celler2.   

Abstract

PURPOSE: The authors' objective was to compare internal dose estimates obtained using the Organ Level Dose Assessment with Exponential Modeling (OLINDA/EXM) software, the voxel S value technique, and Monte Carlo simulation. Monte Carlo dose estimates were used as the reference standard to assess the impact of patient-specific anatomy on the final dose estimate.
METHODS: Six patients injected with 99mTc-hydrazinonicotinamide-Tyr3-octreotide were included in this study. A hybrid planar/SPECT imaging protocol was used to estimate 99mTc time-integrated activity coefficients (TIACs) for kidneys, liver, spleen, and tumors. Additionally, TIACs were predicted for 131I, 177Lu, and 90Y assuming the same biological half-lives as the 99mTc labeled tracer. The TIACs were used as input for OLINDA/EXM for organ-level dose calculation and voxel level dosimetry was performed using the voxel S value method and Monte Carlo simulation. Dose estimates for 99mTc, 131I, 177Lu, and 90Y distributions were evaluated by comparing (i) organ-level S values corresponding to each method, (ii) total tumor and organ doses, (iii) differences in right and left kidney doses, and (iv) voxelized dose distributions calculated by Monte Carlo and the voxel S value technique.
RESULTS: The S values for all investigated radionuclides used by OLINDA/EXM and the corresponding patient-specific S values calculated by Monte Carlo agreed within 2.3% on average for self-irradiation, and differed by as much as 105% for cross-organ irradiation. Total organ doses calculated by OLINDA/EXM and the voxel S value technique agreed with Monte Carlo results within approximately ±7%. Differences between right and left kidney doses determined by Monte Carlo were as high as 73%. Comparison of the Monte Carlo and voxel S value dose distributions showed that each method produced similar dose volume histograms with a minimum dose covering 90% of the volume (D90) agreeing within ±3%, on average.
CONCLUSIONS: Several aspects of OLINDA/EXM dose calculation were compared with patient-specific dose estimates obtained using Monte Carlo. Differences in patient anatomy led to large differences in cross-organ doses. However, total organ doses were still in good agreement since most of the deposited dose is due to self-irradiation. Comparison of voxelized doses calculated by Monte Carlo and the voxel S value technique showed that the 3D dose distributions produced by the respective methods are nearly identical.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25186410     DOI: 10.1118/1.4892606

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  17 in total

1.  Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.

Authors:  James Kelly; Alejandro Amor-Coarasa; Shashikanth Ponnala; Anastasia Nikolopoulou; Clarence Williams; David Schlyer; Yize Zhao; Dohyun Kim; John W Babich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-06       Impact factor: 9.236

2.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

3.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Authors:  Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-04-25       Impact factor: 3.099

4.  Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates.

Authors:  Brian Quinn; Zak Dauer; Neeta Pandit-Taskar; Heiko Schoder; Lawrence T Dauer
Journal:  BMC Med Imaging       Date:  2016-06-18       Impact factor: 1.930

5.  Radiation Dosimetry of Whole-Body Dual-Tracer 18F-FDG and 11C-Acetate PET/CT for Hepatocellular Carcinoma.

Authors:  Dan Liu; Pek-Lan Khong; Yiming Gao; Usman Mahmood; Brian Quinn; Jean St Germain; X George Xu; Lawrence T Dauer
Journal:  J Nucl Med       Date:  2016-01-28       Impact factor: 10.057

6.  Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.

Authors:  Emilie Roncali; Jacek Capala; Stanley H Benedict; Gamal Akabani; Bryan Bednarz; Vikram Bhadrasain; Wesley E Bolch; Jeffrey C Buchsbaum; Norman C Coleman; Yuni K Dewaraja; Eric Frey; Michael Ghaly; Joseph Grudzinski; Robert F Hobbs; Roger W Howell; John L Humm; Charles A Kunos; Steve Larson; Frank I Lin; Mark Madsen; Saed Mirzadeh; David Morse; Daniel Pryma; George Sgouros; Sara St James; Richard L Wahl; Ying Xiao; Pat Zanzonico; Katherine Zukotynski
Journal:  J Nucl Med       Date:  2020-12-04       Impact factor: 10.057

7.  Patient-specific dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in children.

Authors:  Xinchi Hou; Bozena Birkenfeld; Hanna Piwowarska-Bilska; Anna Celler
Journal:  EJNMMI Phys       Date:  2017-10-13

8.  3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.

Authors:  David Sarrut; Jean-Noël Badel; Adrien Halty; Gwenaelle Garin; David Perol; Philippe Cassier; Jean-Yves Blay; David Kryza; Anne-Laure Giraudet
Journal:  EJNMMI Phys       Date:  2017-01-18

9.  BIGDOSE: software for 3D personalized targeted radionuclide therapy dosimetry.

Authors:  Tiantian Li; Licheng Zhu; Zhonglin Lu; Na Song; Ko-Han Lin; Greta S P Mok
Journal:  Quant Imaging Med Surg       Date:  2020-01

10.  A 3D Monte Carlo Method for Estimation of Patient-specific Internal Organs Absorbed Dose for (99m)Tc-hynic-Tyr(3)-octreotide Imaging.

Authors:  Mehdi Momennezhad; Shahrokh Nasseri; Seyed Rasoul Zakavi; Ali Asghar Parach; Mahdi Ghorbani; Ruhollah Ghahraman Asl
Journal:  World J Nucl Med       Date:  2016 May-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.